SIGA Technologies, Inc. (SIGA)
6.34
+0.10
(+1.60%)
USD |
NASDAQ |
Dec 04, 16:00
6.31
-0.03
(-0.47%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 454.02M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 4.48% |
| Valuation | |
| PE Ratio | 6.091 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.633 |
| Price to Book Value | 2.231 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.60 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0043 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 82.20% |
Profile
| SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY. |
| URL | http://www.siga.com |
| Investor Relations URL | https://investor.siga.com/ |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 10, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 29, 2025 |
Ratings
Profile
| SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for medical needs and biothreats. The firm develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY. |
| URL | http://www.siga.com |
| Investor Relations URL | https://investor.siga.com/ |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 10, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 29, 2025 |